Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 13/20 | 0.84 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.84 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25420452 | 0.93 | MAPK10 (0.76) | MAPK10MAPK9PTK2ALKEGFR | |
| SCHEMBL15964228 | 0.93 | MAPK10 (0.85) | MAPK10MAPK9PTK2ALKEGFR | |
| SCHEMBL1231714 | 0.92 | MAPK10 (0.84) | MAPK10MAPK9PTK2ALK | |
| Vs-4718 SCHEMBL47360 | 0.91 | MAPK10 (1.00) | MAPK10MAPK9PTK2ALKEGFR | |
| Vs-4718 SCHEMBL29478885 | 0.91 | MAPK10 (1.00) | MAPK10MAPK9PTK2ALKEGFR | |
| Vs-4718 SCHEMBL29493098 | 0.91 | MAPK10 (1.00) | MAPK10MAPK9PTK2ALKEGFR | |
| Vs-4718 SCHEMBL29381276 | 0.91 | MAPK10 (1.00) | MAPK10MAPK9PTK2ALKEGFR | |
| SCHEMBL25228904 | 0.91 | MAPK10 (0.82) | MAPK10MAPK9PTK2ALKEGFR | |
| Vs-4718 SCHEMBL30354503 | 0.91 | PTK2 (1.00) | MAPK10MAPK9PTK2ALKEGFR | |
| SCHEMBL26184016 | 0.91 | MAPK10 (0.82) | MAPK10MAPK9PTK2ALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024245443-A1 | COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |